共 50 条
HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harbouring BRAF V600E mutation
被引:1
|作者:
Cao, X-X.
[1
]
Wu, Y.
[2
]
Liu, P.
[3
]
Ding, T.
[4
]
Ye, H.
[5
]
Cai, Z.
[6
]
Zhang, Y.
[7
]
Ma, J.
[8
]
Xu, Y.
[9
]
Fu, G.
[9
]
Hu, C.
[10
]
Hou, X.
[10
]
Wang, Q.
[10
]
Zhu, J.
[10
]
Li, J.
[1
]
机构:
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Hematol, Shanghai, Peoples R China
[4] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai, Peoples R China
[5] Fudan Univ, Huashan Hosp, Dept Endocrinol, Shanghai, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China
[7] Guangdong Provincial Peoples Hosp, Dept Orthoped Oncol, Guangzhou, Peoples R China
[8] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China
[9] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China
[10] Shanghai Henlius Biotech Inc, Global Prod Dev, Shanghai, Peoples R China
关键词:
D O I:
10.1016/j.annonc.2023.10.444
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
329MO
引用
收藏
页码:S1599 / S1599
页数:1
相关论文